Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Do clinical and non-specific biological data influence staging?].

T Le Chevalier1

  • 1Institut Gustave-Roussy, Villejuif.

Revue Des Maladies Respiratoires
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Developments in the treatment of early NSCLC: when to use chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same journal

[French version of the guidelines for connective tissue disease-associated ILD].

Revue des maladies respiratoires·2026
Same journal

[Pulmonary expression of an asymptomatic lysosomal storage disorder].

Revue des maladies respiratoires·2026
Same journal

[Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].

Revue des maladies respiratoires·2026
Same journal

[Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].

Revue des maladies respiratoires·2026
Same journal

[Relevance of the ACT score in severe asthma with obesity: A pilot study].

Revue des maladies respiratoires·2026
Same journal

[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

Revue des maladies respiratoires·2026
See all related articles

Extensive work-ups for non-small cell lung carcinoma (NSCLC) are often unnecessary. Only stage III NSCLC requires comprehensive assessment to guide aggressive treatment decisions.

Area of Science:

  • Oncology
  • Diagnostic Imaging

Context:

  • Advancements in imaging technologies prompt extensive diagnostic work-ups for non-small cell lung carcinoma (NSCLC).
  • The clinical utility of comprehensive staging in all NSCLC cases is under scrutiny.

Purpose:

  • To evaluate the impact of extensive work-ups on therapeutic decisions in non-small cell lung carcinoma (NSCLC).
  • To define the appropriate extent of diagnostic assessment based on NSCLC stage.

Summary:

  • For operable (stage I-II) NSCLC without symptoms, extensive work-ups show limited benefit.
  • For metastatic (stage IV) NSCLC, comprehensive assessment is only needed if a metastatic lesion impacts treatment.
  • Locally advanced (stage III) NSCLC warrants a complete assessment to rule out distant metastases before aggressive therapy.

Related Experiment Videos

Impact:

  • Optimizing diagnostic strategies for non-small cell lung carcinoma (NSCLC).
  • Ensuring resource allocation aligns with evidence-based clinical benefits.
  • Guiding therapeutic decisions for NSCLC patients based on stage-specific needs.